Med Trileptal: Another Choice for Partial Onset Epileps
Antiepileptic drug. Pharmacological activity is due primarily to the action of the metabolite, oxcarbazepine monohydroxy derivative. Mechanism of action of oxcarbazepine and its metabolite is mainly related to blockade of potential-dependent sodium channels, which leads to stabilization of overexcited neuronal membranes, inhibition of serial neuronal discharges and reduction of synaptic impulse conduction. This article is about Med Trileptal: Another Choice for Partial Onset Epilepsy.
Increase of potassium ions conductance and modulation of calcium channels activated by high membrane potential contribute to realization of anticonvulsant action. No significant interaction with brain neuromediators or binding to receptors has been observed. Oxcarbazepine and its metabolite have been shown in experimental studies to have pronounced anticonvulsant effects. The effectiveness of oxcarbazepine in epileptic seizures has been demonstrated both during monotherapy and when using oxcarbazepine as part of combination therapy in children and adults.
Indications of active substances of Trileptal drug
Simple and complex partial seizures with or without secondary generalization in adults and children aged 1 month and over. Generalized tonic-clonic epileptic seizures in adults and children aged 2 years and older.
Mode of administration and dosage regimen of a particular drug depend on its form of release and other factors. The optimal dosing regimen is determined by the doctor. You should strictly follow the compliance of the dosage form used for the specific drug indications for use and the dosing regimen. It is taken orally. The initial dose is 8-10 mg/kg body weight/day. Further, the dose is adjusted depending on the treatment regimen, patient’s age, treatment efficacy and renal function. Correction of initial dose and dosage regimen is required for patients with kidney dysfunction (CKG less than 30 ml/min).
Use with caution in patients with known hypersensitivity to carbamazepine because this group of patients may develop hypersensitivity reactions to oxcarbazepine in approximately 25-30% of cases. Patients with no history of hypersensitivity to carbamazepine may also develop hypersensitivity reactions to oxcarbazepine, including multi-organ disorders. In case of development of immediate hypersensitivity reactions oxcarbazepine should be immediately discontinued and alternative therapy should be prescribed.
The experience of use in pregnancy is limited. The available reports indicate a possible association of oxcarbazepine administration in pregnancy with the development of congenital defects.